Parent Checklist for Pediatric Clinical Trial Enrollment

It was overdue. Roughly twenty percent of pediatric clinical trials fail — not necessarily because the underlying therapy was wrong, but because the study design was weak, the enrollment projections were unrealistic, or the protocol asked families to do things no reasonable household could sustain.

I have watched this happen from inside the operations side. A failed trial does not just waste grant money. It can leave children exposed to subtherapeutic dosing, mixed-age cohorts, and immune endpoints that were never properly validated for a developing system. The work you do at the kitchen table before signing consent will not determine whether a study succeeds on its own, but it can help you see whether the trial is designed with your child’s reality in mind.

I have spent the past decade running pediatric cohorts in gene therapy, biologic immunotherapy, and CAR-T protocols. The families who do best are not necessarily the ones with the most medical literacy. They are the ones who treat the enrollment conversation like an audit, not a handshake. The checklist below uses the 2026 reporting frameworks and the regulatory principles that shape how pediatric trials are supposed to run. It is not a substitute for medical or legal advice. It is a way to ask sharper questions before your family takes on the obligations of research.

Navigating the Dual Path of Consent and Assent

Pediatric enrollment runs on a dual-consent model that parents frequently misunderstand. You, as the parent or legal guardian, provide informed consent. Your child provides assent — and that is a different document, a different conversation, and an ongoing process, not a single checkbox.

U.S. federal regulations do not set one hard age threshold that applies to every child and every study. Institutional Review Boards set local policy, and many academic IRBs recommend beginning the assent process around age 7. The operational split often looks something like this:

The exact procedure depends on the IRB, the jurisdiction, the study, and the child’s capacity to understand what is being proposed. Age is a guide, not a complete assessment of maturity. A child with extensive treatment experience may understand clinical procedures very well, while an older adolescent may be overwhelmed by unfamiliar terminology, fear, pain, or the possibility of disappointing their parents.

In the UK, the Medicines for Human Use (Clinical Trials) Regulations draw a different line. Children under 16 cannot give independent consent for Clinical Trials of Investigational Medicinal Products (CTIMPs); young people aged 16 and older are generally presumed capable of consenting on their own. If your child is crossing the 16 threshold during a trial, ask the sponsor and site how that transition is handled. The answer should be specific: whether a new consent discussion is required, which documents will be used, and what happens if the young person no longer agrees to continue.

The point of the dual path is not bureaucracy. It is the formal mechanism that requires the investigator to explain the trial to the child, not only to the adults around them. If your seven-year-old cannot describe, in their own words, what the infusion is intended to do and why blood is being drawn, the investigator may need to slow down and explain it again. That is not a test your child has failed. It is a test of whether the study team has communicated properly.

A signature is not consent. A child who can explain the trial in their own language has been listened to. That is the bar.

Assent also has to be revisited when the child’s understanding changes. A child who could answer only simple questions at the beginning of a study may be able to ask sophisticated questions six months later. The reverse is also true: a child undergoing repeated procedures, hospitalization, or treatment-related fatigue may agree in the room without actually processing what is being proposed.

Ask the site:

• How is assent explained to a child of this age and developmental level?
• Is the child given time to speak without the parent answering every question?
• How does the team document assent over time rather than only at enrollment?
• What happens if the child objects after the parent has already signed?
• How are protocol amendments explained to the child?
• If the child’s ability to understand changes, who reassesses the assent process?
• What is the procedure if the child wants to pause, refuse a procedure, or withdraw?

Parental permission does not erase a child’s developing autonomy. Nor does assent turn a minor into the legal sponsor of the research. These are separate protections, and a serious site should be able to explain the distinction without reaching for legal jargon.

Evaluating Trial Design and Safety Through SPIRIT-C and CONSORT-C

SPIRIT-C 2026 and CONSORT-C 2026 are reporting extensions for pediatric research. They are useful because they make child-specific details harder to leave implicit. The 17 new reporting items should be attributed specifically to SPIRIT-C 2026, rather than jointly to both extensions. CONSORT-C serves a related purpose for reporting completed randomized trials, while SPIRIT-C focuses on what should be described in a trial protocol.

That distinction matters when you are reading a study document. SPIRIT-C and TIDieR-C are reporting frameworks, not automatic quality cutoffs. A protocol does not become unsafe simply because it was written before a particular extension was published, and the absence of a heading named “SPIRIT-C compliance” is not, on its own, proof that the study is badly designed. The useful question is whether the child-specific information these frameworks draw attention to is actually present and understandable.

The TIDieR-C checklist, published in Pediatrics in October 2025, sits alongside SPIRIT-C by focusing on how pediatric interventions are described. Generic trial templates can leave important details vague: how a dose changes as a child grows, how an age-appropriate formulation is administered, how adherence is assessed when a child cannot manage treatment independently, and how the intervention is modified when the child’s condition or developmental stage changes.

When I read a pediatric protocol, I look for the following questions rather than for a certification label:

• How is dosing adjusted for weight, body surface area, age, or developmental stage?
• What happens when the child gains weight or crosses into a different age band?
• How are adverse events graded against pediatric reference ranges?
• Are laboratory values interpreted differently for infants, children, and adolescents?
• What happens if the child develops an intercurrent infection?
• How are missed visits, delayed doses, or temporary treatment interruptions handled?
• What happens if the family withdraws for logistical reasons rather than because the treatment is ineffective?
• How will the trial report results in a way that is interpretable for a developing immune system?
• Are the eligibility criteria likely to create a cohort whose children are too different for the results to be meaningful?

The protocol should make clear not only what happens when everything goes according to plan, but also what happens when a child grows, misses a visit, develops a fever, requires another medicine, or cannot tolerate the intended schedule. Pediatric immunology is not static. A dose that is appropriate at enrollment may require adjustment later. A laboratory value that is unremarkable in an adult may be significant in a younger patient. A trial that treats age as a demographic label rather than a biological variable is asking families to accept avoidable ambiguity.

Safety is more than a list of adverse events

Parents often receive a long adverse-event table and assume that safety has therefore been thoroughly addressed. The more useful issue is how the study team will recognize, grade, investigate, and respond to a problem in a child whose immune system is already abnormal or developing.

Ask who reviews safety data, how quickly serious events are reported, and whether an independent data monitoring committee or DSMB is involved. Ask what happens when a symptom could be caused by the study intervention, the underlying disease, a common childhood infection, or a procedure such as sedation. In immune disorders, those causes can overlap. A fever is not interpreted in a vacuum, and a laboratory change may have a different significance depending on the child’s baseline.

You should also understand stopping rules. What finding would pause dosing? What would stop the individual child from receiving further treatment? What would pause the entire study? Does the protocol allow a dose reduction, a delay, or a return to standard care? These questions are not attempts to predict every complication. They reveal whether the team has thought through the difference between an expected inconvenience and a signal that changes the risk calculation.

Define what “works” means

I also look at the primary efficacy endpoint. Is it a biomarker — a laboratory value that shifts? Or is it a clinical outcome — fewer infections, fewer hospitalizations, improved growth, reduced need for replacement therapy, or improved organ function? Biomarker endpoints are often faster and more practical, but they are surrogates. In pediatric immunotherapy, particularly for primary immunodeficiency, the gap between a shifted biomarker and a clinically meaningful outcome can be substantial.

Make sure the trial is designed to detect the outcome that actually matters to your family, not only the one that is convenient to measure. That does not make a biomarker endpoint useless. Early-phase studies often need laboratory measures to establish whether an intervention is producing the expected biological effect. The question is whether the investigators are honest about what the marker can and cannot show.

Ask whether the biomarker has been linked to outcomes that matter in children, whether the study will continue to track clinical events, and how the researchers will interpret a result that improves in the laboratory without changing the child’s day-to-day health. A good answer may still be uncertain. Early research is allowed to be uncertain. What it should not be is vague about the uncertainty.

Logistical Realities: School, Travel, and Reimbursement

Information about participant burden may appear in several parts of a protocol or consent package: the schedule of assessments, visit calendar, procedure descriptions, risk section, reimbursement policy, and practical instructions from the site. Do not assume there is one universal “burden section,” or that the information will be presented in a single convenient place. It may be spread across documents, written in committee prose, or described in a way that underestimates what a visit means for a real family.

Read the schedule of assessments alongside the consent form. Then ask questions that force the abstract timeline into ordinary life:

• How many visits does the trial require in the first 90 days, and how many of those are inpatient?
• What is the longest expected interval between visits once the child enters the maintenance phase?
• Which visits can be completed locally, and which require travel to the central study site?
• What happens if the family lives more than two hours away?
• Will the child need a central line, sedation, repeated imaging, or prolonged monitoring?
• Are those procedures included in the burden estimate and the reimbursement policy?
• What happens if a visit is canceled because of fever, hospitalization, weather, or a site staffing problem?
• Can a missed assessment be rescheduled, or does it affect eligibility and data analysis?

The phrase “reimbursement available” is not a policy. It tells you almost nothing about when money arrives, which expenses qualify, or whether a parent has to pay upfront. Ask for the written reimbursement schedule. Clarify travel, lodging, meals, parking, mileage, flights, local transport, and the expenses of an accompanying caregiver. Ask whether receipts are required, how far in advance arrangements must be made, and what happens if the family cannot front the cost.

A family may be technically eligible for reimbursement and still be unable to manage a series of hotel bookings, parking charges, missed workdays, and delayed repayment. This is not a minor administrative inconvenience. Financial strain is one of the ways a feasible study becomes an impossible one.

School planning deserves the same level of attention. A trial may describe a visit as “one day,” but the practical absence can include travel the night before, the appointment itself, recovery afterward, and a child who is too exhausted to return to class the next morning. Ask the site for a calendar that shows the likely rhythm of visits rather than a list of isolated procedures.

For adolescents, ask how the study handles examinations, sports, employment, privacy, and transportation when a parent cannot accompany every visit. For younger children, ask whether a caregiver can remain present during procedures and what support exists when siblings have to travel too. If the intervention involves immune suppression or a period of heightened infection risk, ask how school attendance and exposure precautions may change. The answer should be individualized; there is no single school plan that fits every immunotherapy protocol.

In my experience running these cohorts, the families who burn out are not necessarily the ones with the sickest children. They are the ones who underestimated the visit cadence and discovered, four months in, that the monthly trip was actually a weekly trip once titration started.

Read the schedule of assessments before you read the science. If the visit cadence is incompatible with your family’s actual life, the science will not save you.

Assessing the 20% Failure Risk

The one-in-five failure figure is not a prediction about your child’s trial. It is a reminder that a promising intervention can still produce an uninformative study. Before enrollment, ask what could make this particular trial fail: inappropriate design, suboptimal planning, or inadequate enrollment.

Is the design appropriate for the question?

Start with the control arm. In pediatric gene therapy and CAR-T trials, placebo controls may be ethically or practically impossible. The comparator may instead be standard of care or an external historical cohort. External comparators can be useful, but they are more vulnerable to differences in patient selection, treatment history, follow-up, and supportive care than randomized controls.

Ask the investigator:

1. What is the trial designed to detect?

2. What would count as a clinically meaningful difference?

3. Why was this comparator chosen?

4. What are the main limitations of comparing these children with the proposed control group?

5. How will the analysis account for differences in age, disease severity, prior treatment, and baseline health?

If the team cannot answer those questions clearly, the design may be under-specified. That does not automatically mean you should decline. It does mean you should understand whether the study is exploratory, confirmatory, or intended to support a later regulatory decision.

You should also ask whether the enrolled children are actually comparable. A rare-disease study may need to include a wide age range or children with different treatment histories. That can be reasonable, but it complicates interpretation. If a treatment appears to work better in one age band, the study needs a way to distinguish a genuine age-related effect from differences in prior therapy, baseline health, or follow-up time.

In immunotherapy studies, the phrase “clinical response” can conceal several different things. It may mean a change in immune-cell numbers, a reduction in infection frequency, freedom from replacement therapy, improved organ function, or survival through a defined follow-up period. Ask the team to define response in plain language and explain what would count as meaningful improvement for your child, not merely a statistically detectable change.

Does the planning match the uncertainty?

Look at the sample size. Pediatric trials are often small because the diseases are rare, but a small trial has wide confidence intervals, and a positive result in a 12-patient cohort is not the same as a positive result in a 60-patient cohort. The number of participants affects how much uncertainty will remain when the study ends.

Ask whether the trial has an independent data monitoring committee and how often it meets. Ask what information the committee reviews, whether safety reviews are separate from efficacy analyses, and whether the committee can recommend pausing or modifying the study. A monitoring committee is not a guarantee of safety, but its role should be defined rather than mentioned as a piece of reassuring language.

Ask what happens if the planned number of participants cannot be reached. Will the investigators extend recruitment, add sites, combine data with another cohort, amend the eligibility criteria, or stop the study? None of those choices is automatically right or wrong. What matters is whether they have been considered in advance and whether their consequences for interpretation are understood.

A small sample can also make a treatment look more consistent than it is. A handful of responders may create an encouraging early signal without establishing how reliably the intervention works across children. One serious adverse event can materially change the safety profile. Ask how the study will describe uncertainty when the final cohort is smaller than planned.

Is enrollment realistic?

Inadequate enrollment can undermine an otherwise careful trial. Ask how many sites are recruiting, what the enrollment target is, and how many participants have enrolled to date. If a study has been open for a long time but has recruited only a small fraction of its target, ask what the team believes is slowing recruitment and what will happen if that does not change.

Slow recruitment may reflect narrow eligibility criteria, competing studies, a limited number of specialist centers, or a treatment that families reasonably find difficult to accept. It may also indicate that the original assumptions about the available patient population were unrealistic.

Useful questions include:

• How many children are currently being screened?
• How many have failed screening, and for what general reasons?
• How many sites are actively enrolling rather than merely listed?
• Is the recruitment target still realistic?
• What happens to enrolled children’s data if the trial closes before reaching its target?
• Will follow-up continue if recruitment stops?
• If the protocol changes to improve recruitment, will families be asked to reconsider consent?

Regulator-side, the EMA has been pushing earlier engagement through stepwise Paediatric Investigation Plans. Between 2023 and 2025, the agency received 27 eligibility requests and adopted 8 stepwise PIPs specifically to support pediatric medicines for unmet medical needs. Ask whether the trial is operating under a stepwise PIP and how that affects the pediatric development and regulatory timeline.

A stepwise PIP can change when pediatric studies are initiated, how development is staged, and when regulators review the available evidence. It is not, by itself, a guarantee of a particular post-trial access arrangement.

That last point matters because families often hear “pediatric development plan” and assume it answers the question of what happens after the study ends. It may not. Ask separately whether there is an extension study, a continued-access mechanism, or another plan for children who are benefiting from the intervention. Those arrangements depend on the study, the sponsor, the treatment, and the applicable rules. They should be described in the consent materials or explained directly by the research team, rather than inferred from the existence of a PIP.

Integrating Child-Specific Needs with TIDieR-C

The Template for Intervention Description and Replication in Children and Adolescents, or TIDieR-C, was published in Pediatrics in October 2025. It is a reporting framework for describing pediatric interventions in enough detail that clinicians, researchers, and families can understand what was actually delivered. It is not a pass-or-fail badge for an individual trial.

The 13 pediatric considerations are not a checklist for parents to memorize. They are prompts for identifying the details that generic intervention descriptions often leave out. For a family considering an immunotherapy or clinical trial, translate them into practical questions:

1. Who is the intervention intended for? Ask which age groups, developmental stages, disease subtypes, and baseline immune profiles the intervention was designed to address.

2. What exactly is given? Clarify the product, formulation, dose, concentration, and whether the material is investigational, modified, or combined with standard treatment.

3. How is the dose determined? Ask whether dosing uses weight, body surface area, age, immune markers, prior treatment, or another calculation.

4. How does the dose change as the child grows? A growing child is not a stable laboratory unit. Find out when the team recalculates the dose and what triggers an adjustment.

5. How is the intervention administered? Ask about route, infusion time, injection technique, central access, premedication, and monitoring.

6. Is the formulation appropriate for the child’s age? A treatment that is straightforward for an adult may be difficult to swallow, measure, tolerate, or administer to a young child.

7. How is adherence assessed? Clarify who gives each dose, what happens when a child refuses or vomits medication, and how missed or partial doses are recorded.

8. What supportive care is required? Ask about prophylactic medicines, replacement therapy, hydration, dietary restrictions, infection precautions, and laboratory monitoring.

9. What counts as a protocol modification? The team should explain how it responds to growth, organ-function changes, intercurrent illness, treatment toxicity, or a change in the child’s clinical status.

10. How long does each treatment encounter last? “Administration” may not include preparation, observation, recovery, or emergency assessment if a symptom develops.

11. How is the child’s experience measured? Ask whether the study records pain, fatigue, anxiety, sleep, school attendance, or other outcomes that may not appear in an immune-cell count.

12. How is the intervention delivered consistently across sites? If several hospitals participate, ask how training, preparation, administration, and safety monitoring are standardized.

13. What information is needed to reproduce or interpret the treatment? Find out whether the study will document timing, dose changes, deviations, interruptions, and the reasons behind them.

These questions do not turn a parent into a protocol reviewer. They reveal whether the intervention has been described as something that happens to a real child or as an abstract dose in a spreadsheet.

Development changes the intervention

Age affects more than consent language. It can influence pharmacokinetics, organ function, immune response, ability to report symptoms, tolerance of procedures, and dependence on caregivers. A toddler may not be able to describe tingling, nausea, or early neurological symptoms. An adolescent may describe them clearly but hesitate to report them if they believe doing so could remove them from the trial.

Ask how the study accounts for these differences. Does the team use parent-reported and child-reported outcomes? Are there age-appropriate tools for pain, fatigue, quality of life, or functioning? Is the child’s school attendance recorded? Are changes in growth, puberty, or developmental milestones monitored when they are relevant to the therapy?

For a pediatric immunotherapy trial, the most important endpoint may not appear on the first page of the protocol. A laboratory marker can move in the expected direction while the child continues to be hospitalized, misses school, or relies on the same supportive treatment. Conversely, a child may experience a meaningful improvement before the study’s chosen biomarker fully reflects it. The protocol should explain how these different forms of evidence will be handled.

Ask what happens when the child says no

The practical test of a child-centered study is not how warmly the team speaks during the first visit. It is how the team responds when the child is frightened, exhausted, resistant, or no longer willing to continue.

Ask whether the protocol permits breaks, revised explanations, psychological support, procedural preparation, or changes in scheduling. Ask which procedures require assent again and which can be performed under the original consent. Ask what happens if the child agrees to treatment but refuses a research-only blood draw. The answer should distinguish care that is clinically necessary from procedures performed only to collect study data.

A child’s refusal may not automatically end every aspect of participation, but it must be taken seriously. The site should explain the options without making the child feel responsible for the study’s success. The purpose of pediatric assent is not to teach children to comply with research. It is to give them a meaningful role in deciding what happens to their bodies.

The Conversation Before the Signature

Bring the consent documents home if the site permits it. Read them when you are not sitting in a clinic room with a clock running and a child waiting. Mark every sentence that uses a broad term — “close monitoring,” “reasonable travel,” “possible benefit,” “standard follow-up,” “reimbursement available” — and ask the team to translate it into the actual schedule and actual responsibility.

A useful preparation process is simple:

1. Write down the child’s current treatment schedule, school obligations, transportation limits, and the people available to provide care.

2. Put the trial’s visits, procedures, admissions, and likely recovery periods beside that existing schedule.

3. Separate research-only procedures from procedures that would occur as part of ordinary clinical care.

4. Ask which costs are covered, which are billed to insurance, which must be paid upfront, and what happens when an adverse event requires care outside the study site.

5. Ask how long follow-up lasts and what happens after the formal study period ends.

6. Ask the child what they understand, what they fear, and which parts of participation they consider unacceptable.

7. Take the unanswered questions back to the investigator rather than relying on assumptions made in the parking lot.

The most revealing answers are often not the most reassuring ones. A team that says, “We do not know yet, but this is how we will monitor it,” may be more trustworthy than a team that presents every uncertainty as already solved. Pediatric research necessarily involves unknowns. The ethical obligation is to make those unknowns visible.

Enrollment is not a verdict on whether the intervention is good or bad. It is a decision about whether this study, at this site, with this schedule and this level of uncertainty, is workable for your child and your family. Reporting frameworks such as SPIRIT-C, CONSORT-C, and TIDieR-C can help expose missing details, but they do not make the decision for you. They give you better questions.

The final question is therefore not simply, “Is this treatment promising?” It is: “Do we understand what participation requires, what the study can realistically tell us, and what protections remain if the plan changes?” If the answer is yes, the signature becomes the record of an informed decision rather than a leap taken under pressure.